• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

输血传播细菌感染(TTBI)与血液成分责任评分2:对2000 - 2007年法国电子拟合数据库的回顾性分析。输血传播细菌感染验证工作组

[Transfusion transmitted bacterial infectious (TTBI) with blood component accountability score 2: Retrospective analysis of the French e-fit database 2000-2007. Groupe de travail–validation des IBTT (Working group for validation of transfusion-transmitted bacterial infections)].

作者信息

Delbosc A, Lafeuillade B, Petermann R, Eb F, Ounnoughene N

机构信息

Hémovigilance, agence régionale de santé de Franche-Comté, 3, avenue Louise-Michel, 25044 Besançon cedex, France.

出版信息

Transfus Clin Biol. 2011 Feb;18(1):26-35. doi: 10.1016/j.tracli.2010.12.002.

DOI:10.1016/j.tracli.2010.12.002
PMID:21310643
Abstract

PURPOSE OF THE STUDY

Transfusion transmitted bacterial infection is an adverse reaction occurring in a patient during blood transfusion and due to the presence of bacteria in the blood component. For each transfusion transmitted bacterial infection suspicion, clinical and biological investigations should allow to either affirm the accountability of the transfused product in the occurrence of the infection (accountability score 4) or exclude it (accountability score 0). However, among 60,175 adverse reaction sheets extracted from the French e-FIT database (AFSSAPS), 143 are classified as transfusion transmitted bacterial infection diagnosis and 97 of them show a score of accountability 2 (possible). This study aims to analyze these 97 adverse reaction sheets and search for the reasons that led the haemovigilance network actors not to refine the degree of accountability in line with an exclusion or a confirmation of transfusion origin.

METHOD

During collective reading sessions, each adverse reaction sheet among the 97 extracted was re-analyzed with an accountability criteria grid, built beforehand, and proposed in the technical guide sheet for transfusion transmitted bacterial infection (e-Fit AFSSAPS).

RESULTS

Among the 97 analyzed adverse reaction sheets with a score accountability of 2: 12.4 % were considered as "non-analysable"; 54% were reclassified in another diagnosis category: non haemolytic febrile reaction (n=12), unknown diagnosis (n=17); patient infection before transfusion (n=23); blood component's "smear" (n=9); retrograde contamination of blood component (n=5). Finally, only 18.5% adverse reaction sheets (n=18) were maintained with a true diagnosis of transfusion transmitted bacterial infection an accountability score of 2. These cases were in agreement with those described in number 2, 3 or 4 in the annex sheet "Fiche Technique TTBI". 70% of adverse reaction sheets reclassified under another diagnosis as transfusion transmitted bacterial infection had been declared between 2000 and 2004. In order to improve transfusion transmitted bacterial infection suspicions diagnosis approach and to guide the French haemovigilance network in the investigations following a transfusion transmitted bacterial infection suspicion, the group propose recommendations after each adverse reaction sheets category analysis.

CONCLUSION

The improvement measures taken as part of the French haemovigilance declaration framework allowed to perfect the data quality of transfusion transmitted bacterial infection. Progresses are still to be made to improve clinical and biological declaration, in order to precise the accountability of a blood component in the occurrence of an adverse transfusion transmitted bacterial infection effect. Tracking transfusion transmitted bacterial infection notifications by a group of experts at the national level is still recommended.

摘要

研究目的

输血传播细菌感染是患者在输血过程中因血液成分中存在细菌而发生的不良反应。对于每一例输血传播细菌感染疑似病例,临床和生物学调查应能够确认输血产品在感染发生中的责任(责任评分4)或排除其责任(责任评分0)。然而,在从法国电子FIT数据库(AFSSAPS)中提取的60175份不良反应报告中,143份被归类为输血传播细菌感染诊断,其中97份显示责任评分为2(可能)。本研究旨在分析这97份不良反应报告,并寻找导致血液警戒网络参与者未根据输血来源的排除或确认来细化责任程度的原因。

方法

在集体阅读会议期间,使用预先构建并在输血传播细菌感染技术指导手册(电子FIT AFSSAPS)中提出的责任标准网格,对提取的97份不良反应报告中的每一份进行重新分析。

结果

在97份责任评分为2的分析不良反应报告中:12.4%被认为“无法分析”;54%被重新归类到另一个诊断类别:非溶血性发热反应(n = 12)、不明诊断(n = 17);输血前患者感染(n = 23);血液成分“涂片”(n = 9);血液成分逆行污染(n = 5)。最后,只有18.5%的不良反应报告(n = 18)被维持为输血传播细菌感染的确诊,责任评分为2。这些病例与附件“输血传播细菌感染技术表”中第2、3或4项所述病例一致。在2000年至2004年期间宣布了70%被重新归类为输血传播细菌感染的另一种诊断的不良反应报告。为了改进输血传播细菌感染疑似病例的诊断方法,并在输血传播细菌感染疑似病例后指导法国血液警戒网络进行调查,该小组在对每个不良反应报告类别进行分析后提出了建议。

结论

作为法国血液警戒申报框架一部分采取的改进措施有助于完善输血传播细菌感染的数据质量。为精确血液成分在不良输血传播细菌感染效应发生中的责任,仍需在改进临床和生物学申报方面取得进展。仍建议由一组国家层面的专家跟踪输血传播细菌感染通知。

相似文献

1
[Transfusion transmitted bacterial infectious (TTBI) with blood component accountability score 2: Retrospective analysis of the French e-fit database 2000-2007. Groupe de travail–validation des IBTT (Working group for validation of transfusion-transmitted bacterial infections)].输血传播细菌感染(TTBI)与血液成分责任评分2:对2000 - 2007年法国电子拟合数据库的回顾性分析。输血传播细菌感染验证工作组
Transfus Clin Biol. 2011 Feb;18(1):26-35. doi: 10.1016/j.tracli.2010.12.002.
2
[Recipients adverse reactions: guidance supports].[接受者不良反应:指导支持]
Transfus Clin Biol. 2010 Dec;17(5-6):366-74. doi: 10.1016/j.tracli.2010.09.148. Epub 2010 Nov 3.
3
Residual risk and retrospective analysis of transfusion-transmitted bacterial infection reported by the French National Hemovigilance Network from 2000 to 2008.法国国家血液监测网络2000年至2008年报告的输血传播细菌感染的残余风险及回顾性分析
Transfusion. 2015 Mar;55(3):636-46. doi: 10.1111/trf.12883. Epub 2014 Sep 26.
4
[Adverse unidentified transfusion reactions in five French regions: analysis, results, propositions].[法国五个地区的不明输血不良反应:分析、结果与建议]
Transfus Clin Biol. 2010 Feb;17(1):20-7. doi: 10.1016/j.tracli.2009.11.002. Epub 2010 Feb 12.
5
Transfusion-transmitted bacterial infection: risks, sources and interventions.输血传播的细菌感染:风险、来源及干预措施
Vox Sang. 2004 Apr;86(3):157-63. doi: 10.1111/j.0042-9007.2004.00410.x.
6
[Factsheets: support in the analysis of recipients' adverse reactions].[情况说明书:支持对接受者不良反应的分析]
Transfus Clin Biol. 2012 Nov;19(4-5):187-94. doi: 10.1016/j.tracli.2012.07.017. Epub 2012 Sep 19.
7
[What to do in case of adverse event in recipient at the French National Blood Service?].
Transfus Clin Biol. 2012 Nov;19(4-5):182-6. doi: 10.1016/j.tracli.2012.07.022. Epub 2012 Sep 21.
8
[Hypotension and adverse transfusion reactions: from the associated clinical signs to the hypotensive transfusion reaction].[低血压与输血不良反应:从相关临床体征到低血压性输血反应]
Transfus Clin Biol. 2009 Mar;16(1):12-20. doi: 10.1016/j.tracli.2009.01.004. Epub 2009 Mar 26.
9
Adverse transfusion reactions in patients with aplastic anaemia or myelodysplastic syndromes.再生障碍性贫血或骨髓增生异常综合征患者的输血不良反应
Vox Sang. 2019 May;114(4):349-354. doi: 10.1111/vox.12765. Epub 2019 Feb 28.
10
[Control of the bacterial risk of transfusion in France in 2013].[2013年法国输血细菌风险的控制]
Transfus Clin Biol. 2013 May;20(2):174-81. doi: 10.1016/j.tracli.2013.03.007. Epub 2013 Apr 25.

引用本文的文献

1
Improving platelet transfusion safety: biomedical and technical considerations.提高血小板输注安全性:生物医学与技术考量
Blood Transfus. 2016 Mar;14(2):109-22. doi: 10.2450/2015.0042-15. Epub 2015 Nov 16.